[
  {
    "question": "A 58-year-old woman with HIV infection is brought to the emergency department because of a 2-week history of headaches, blurred vision, and confusion. Her current medications include antiretroviral therapy and trimethoprim-sulfamethoxazole. Neurological examination shows ataxia and memory impairment. Her CD4+ T-lymphocyte count is 90/\u03bcL. Analysis of her cerebrospinal fluid analysis shows lymphocytic predominant pleocytosis, and PCR is positive for Epstein-Barr virus DNA. An MRI of the brain with contrast shows a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum. What is the most likely diagnosis?",
    "answer": "Based on the clinical presentation, low CD4 count, the presence of a solitary ring-enhancing brain lesion, and a positive Epstein-Barr virus PCR in the cerebrospinal fluid, the most likely diagnosis is **Primary CNS Lymphoma (PCNSL)**.\n\nIn individuals with advanced HIV, PCNSL is strongly associated with EBV infection, and detecting EBV DNA in the CSF is highly suggestive of this diagnosis.",
    "true_answer": "The most likely diagnosis for a patient with HIV, presenting with neurological symptoms and a solitary ring-enhancing lesion, is primary cerebral lymphoma."
  },
  {
    "question": "A 25-year-old sexually active male presents to an internal medicine physician for a routine health check up after having several unprotected sexual encounters. After appropriate testing the physician discusses with the patient that he is HIV+ and must be started on anti-retroviral treatment. What medication prescribed acts on the gp41 subunit of the HIV envelope glycoprotein?",
    "answer": "The medication that acts on the gp41 subunit of the HIV envelope glycoprotein is **enfuvirtide (Fuzeon)**. It is a fusion inhibitor.",
    "true_answer": "The medication that targets the gp41 subunit of the HIV envelope glycoprotein is enfuvirtide."
  },
  {
    "question": "A 27-year-old man presents with a 2-week history of fever, malaise, and occasional diarrhea. On physical examination, the physician notes enlarged inguinal lymph nodes. An HIV-1 detection test is positive. Laboratory studies show a CD4+ count of 650/mm3. This patient is most likely currently in what stage of HIV infection?",
    "answer": "Based on the symptoms (fever, malaise, diarrhea, lymphadenopathy) suggestive of acute retroviral syndrome, a recent positive HIV test, and a CD4 count within the normal range, this patient is most likely in the **Acute/Primary HIV infection** stage.",
    "true_answer": "This patient is most likely currently in the stage of acute HIV infection."
  },
  {
    "question": "A 50-year-old male with HIV presents to his primary care provider complaining of persistent fevers and night sweats over the past four months. He has also experienced a productive cough. He has been poorly adherent to his HAART regimen. His past medical history also includes gout, hypertension, and diabetes mellitus. He takes allopurinol, enalapril, and metformin. His temperature is 100.9\u00b0F (38.3\u00b0C), blood pressure is 125/75 mmHg, pulse is 95/min, and respirations are 20/min. His CD4 count is 85 cell/mm^3 and a PPD is negative. A chest radiograph reveals cavitations in the left upper lobe and left lower lobe. Bronchoalveolar lavage reveals the presence of partially acid-fast gram-positive branching rods. A head CT is negative for any intracranial process. What is the mechanism of action of the most appropriate drug for managing this patient\u2019s condition?",
    "answer": "This patient's presentation with fevers, cough, cavitary lung lesions, low CD4 count, and partially acid-fast gram-positive branching rods on BAL is highly suggestive of Nocardiosis.\n\nThe most appropriate drug for managing Nocardiosis is typically trimethoprim-sulfamethoxazole (TMP-SMX).\n\nThe mechanism of action of TMP-SMX is the synergistic inhibition of bacterial folic acid synthesis:\n*   **Sulfamethoxazole** inhibits the enzyme dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydrofolic acid.\n*   **Trimethoprim** inhibits the enzyme dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid.\n\nThis dual blockade disrupts critical steps in the pathway bacteria use to make folic acid, which is essential for synthesizing DNA, RNA, and proteins. Humans get folic acid from their diet, so their pathway is not inhibited.",
    "true_answer": "The mechanism of action of the most appropriate drug to manage this patient's condition is inhibition of bacterial folic acid synthesis."
  },
  {
    "question": "A physician scientist is looking for a more efficient way to treat HIV. Patients infected with HIV mount a humoral immune response by producing antibodies against the HIV envelope proteins. These antibodies are the same antibodies detected by the ELISA and western blot assays used to diagnose the disease. The physician scientist is trying to generate a new, more potent antibody against the same HIV envelope proteins targeted by the natural humoral immune response. Of the following proteins, which is the most likely target of the antibody he is designing?",
    "answer": "Based on the information provided, the natural humoral immune response produces antibodies against the HIV envelope proteins gp120 and gp41. These are the proteins on the surface of the virus that are critical for binding to and entering host cells.\n\nThe diagnostic tests like ELISA and Western Blot detect antibodies against several HIV proteins, including envelope proteins.\n\nThe physician scientist is looking to generate a more potent antibody against these *same* envelope proteins targeted by the natural immune response. Antibodies that neutralize the virus by blocking entry primarily target the envelope proteins.\n\nBetween the two main envelope proteins:\n*   gp120 is the outer subunit that binds to the CD4 receptor and co-receptor on target cells.\n*   gp41 is the transmembrane subunit that mediates fusion of the viral and cellular membranes.\n\nBoth are targets of the humoral response and can be targets for neutralizing antibodies. However, gp120, being the outermost protein involved in initial attachment, is a prominent target for antibodies aimed at blocking viral entry and is a major component of the envelope spike.\n\nTherefore, the most likely target of the new, potent antibody designed to enhance the natural response against HIV envelope proteins, particularly for neutralization, is **gp120**.",
    "true_answer": "The most likely target of the antibody being designed for HIV envelope proteins is gp120."
  },
  {
    "question": "A 50-year-old HIV-positive male presents to the ER with a two-day history of fever and hemoptysis. Chest radiograph shows a fibrocavitary lesion in the right middle lobe. Biopsy of the afflicted area demonstrates septate hyphae that branch at acute angles. What is the most likely causal organism?",
    "answer": "Based on the septate hyphae branching at acute angles found on biopsy in an immunocompromised patient with a cavitary lung lesion, the most likely causal organism is *Aspergillus*.",
    "true_answer": "The most likely causal organism for the symptoms presented is Aspergillus fumigatus."
  },
  {
    "question": "A 43-year-old man with HIV infection comes to the physician because of a 2-week history of progressive diarrhea and a 3-kg (6.6-lb) weight loss. During this period, he has had 3\u20134 episodes of watery stools daily, with multiple instances of blood in the stool. He is currently receiving antiretroviral therapy with zidovudine, lamivudine, and dolutegravir. Physical examination shows pallor and dry mucous membranes. A colonoscopy shows multiple linear ulcers. Polymerase chain reaction of a stool sample is positive for cytomegalovirus. Treatment with valganciclovir is begun. Adding this drug to his current medication regimen puts this patient at greatest risk for what specific adverse effects?",
    "answer": "Adding valganciclovir to this patient's regimen, which includes zidovudine, places him at greatest risk for **increased myelosuppression**. Both valganciclovir and zidovudine can cause myelosuppression, particularly **neutropenia** and **anemia**, leading to an additive or synergistic effect on bone marrow suppression.",
    "true_answer": "Treatment with valganciclovir places the patient at increased risk for pancytopenia."
  },
  {
    "question": "A 28-year-old G1P0 woman at 16 weeks estimated gestational age presents for prenatal care. Routine prenatal screening tests are performed and reveal a positive HIV antibody test. The patient is extremely concerned about the possible transmission of HIV to her baby and wants to have the baby tested as soon as possible after delivery. Which of the following would be the most appropriate diagnostic test to address this patient\u2019s concern?",
    "answer": "That's a very common and important concern. It's crucial to test the baby correctly.\n\nStandard antibody tests (like the initial test done on the mother) are not suitable for diagnosing HIV infection in a newborn because maternal antibodies can cross the placenta and be present in the baby's blood for many months, giving a false positive result.\n\nThe most appropriate diagnostic test for a newborn or infant born to an HIV-positive mother is a test that detects the virus itself, not the antibodies. This is typically an **HIV nucleic acid test (NAT)**, such as an **HIV DNA PCR** or **HIV RNA PCR**. These tests look for the virus's genetic material.\n\nHIV DNA PCR is frequently used for initial screening in newborns exposed to HIV.",
    "true_answer": "The most appropriate test for early HIV diagnosis in a newborn is the polymerase chain reaction (PCR) for HIV RNA."
  },
  {
    "question": "A 32-year-old man comes to the office for a routine health maintenance examination. He admits to recently having an affair several months ago and requests STD testing. One week later, the results of a fourth-generation HIV antibody and antigen test return positive. The patient is counseled on the test result. The patient requests that his diagnosis not be disclosed to anyone, including his wife. The man's wife is also the physician's patient. What should be the most appropriate next step by the physician?",
    "answer": "Okay, this is a challenging but common scenario in HIV care. As a senior physician, I would guide the junior clinician on the following most appropriate next steps:\n\n1.  **Counsel the patient strongly:** Emphasize the critical importance of disclosing his HIV status to his wife immediately. Explain the significant health risks to her (potential transmission, delayed diagnosis/treatment for her if infected) and the ethical and potential legal obligations regarding partner notification.\n2.  **Explore barriers to disclosure:** Understand *why* he is reluctant to tell his wife. Address his fears (e.g., fear of rejection, conflict, divorce).\n3.  **Offer support for disclosure:** Offer to help him plan *how* to tell her, or even offer to be present when he tells her, if he wishes.\n4.  **Explain mandatory reporting and partner notification:** Inform the patient that HIV is a reportable condition to public health authorities. Explain the process of partner notification services provided by public health departments, which are designed to inform partners of potential exposure while often protecting the identity of the index patient, *especially* if the patient is unwilling to disclose. Clarify that failure to disclose and unwillingness to allow public health notification would present a difficult situation regarding the physician's duty to warn an identifiable at-risk partner, although direct disclosure by the physician is typically a last resort and governed by specific state laws and ethical guidelines.\n\nThe most appropriate *immediate* next step after the patient requests non-disclosure is to initiate this comprehensive counseling process with the patient himself regarding the necessity of disclosure to his wife and the subsequent steps that will be taken if he does not comply, involving public health. You cannot simply agree to keep this information from his wife given the direct and imminent risk to her health.",
    "true_answer": "The physician should report the HIV infection to the national health authorities while maintaining confidentiality per regulations."
  },
  {
    "question": "A 41-year-old woman presents with acute onset severe epigastric pain radiating to the back that began a few hours ago. She also complains of nausea and has vomited twice in the past hour. She denies any history of similar symptoms or trauma in the past. Past medical history is significant for diabetes type 2 and HIV infection diagnosed 6 months ago long-standing mild intermittent asthma, and generalized anxiety disorder. She takes metformin for her diabetes but does not remember the names of her HIV medications. She reports moderate social alcohol use. Her vital signs include temperature 37.6\u00b0C (99.6 \u00b0F), pulse 95/min, blood pressure 110/74 mm Hg, respiratory rate 12/min Her body mass index (BMI) is 21 kg/m2. Laboratory findings are significant for the following: Serum amylase: 415 U/L, Serum lipase: 520 U/L. A contrast CT of the abdomen reveals an edematous pancreas with peripancreatic fluid collection with a normal gallbladder. What is the most likely etiology of this patient\u2019s condition?",
    "answer": "Based on the clinical presentation, elevated serum amylase and lipase, and CT findings consistent with acute pancreatitis, the most likely etiology in this patient is drug-induced pancreatitis, particularly due to her antiretroviral therapy.\n\nWhile alcohol is a common cause, certain HIV medications, historically some nucleoside reverse transcriptase inhibitors and protease inhibitors, are well-known causes of pancreatitis. Other possibilities include hypertriglyceridemia (which can be associated with diabetes and some HIV medications) and idiopathic causes, but medication effect is a strong consideration in this context, especially since gallstones were excluded. Determining the specific HIV regimen is crucial to confirm this suspicion.",
    "true_answer": "It is most likely related to their HIV medication."
  },
  {
    "question": " A 28-year-old primigravid woman at 38 weeks' gestation is brought to the emergency department in active labor. She has not had regular prenatal care. She has a history of HIV infection but is not currently on antiretroviral therapy. Her previous viral load is unknown. Treatment with intravenous zidovudine is begun to reduce perinatal transmission of the virus. What biological process is most likely disrupted by this drug\u2019s action mechanism?",
    "answer": "Zidovudine (AZT) is a nucleoside reverse transcriptase inhibitor (NRTI). It disrupts the biological process of **reverse transcription**.\n\nHIV uses the enzyme reverse transcriptase to convert its RNA genome into DNA. Zidovudine, after being converted into its active triphosphate form, acts as a faulty building block (a thymidine analog). It gets incorporated into the growing viral DNA chain and causes chain termination, preventing the reverse transcriptase from completing the conversion of RNA to DNA.",
    "true_answer": " Zidovudine affects elongation of viral DNA by inhibiting the viral reverse transcriptase enzyme."
  },
  {
    "question": "What is known about DNA methylation profiles in patients with latent HIV-1 or with an active infection?",
    "answer": "Research indicates that HIV-1 infection, whether active or latent, is associated with alterations in DNA methylation profiles.\n\n*   **Active Infection:** In individuals with active, untreated HIV, global and gene-specific DNA methylation changes are observed in circulating immune cells compared to uninfected individuals. These changes are often linked to chronic immune activation, inflammation, and dysregulation of gene expression.\n*   **Latent Infection:** In cells harboring latent HIV, methylation of the integrated provirus (particularly in the 5' LTR region) is a key epigenetic mark associated with transcriptional silencing and viral latency. Furthermore, methylation changes in host genes within these latently infected cells may contribute to their persistence and resistance to elimination.\n\nComparing the *overall* methylation profiles between actively infected individuals and those with well-controlled latent infection (on antiretroviral therapy) reveals differences, often reflecting the systemic effects of active replication and inflammation versus the more specific changes associated with the reservoir in treated individuals. These methylation changes are complex and an active area of investigation to understand pathogenesis, latency, and potential therapeutic targets.",
    "true_answer": "DNA methylation is correlated with and functionally linked to HIV-1 pathogenesis and latency. In active infection, HIV-1 infection is associated with global changes in host cell DNA methylation patterns, while in latent infection, methylation of the proviral DNA, particularly in the 5\u2019 LTR promoter and intragenic regions, plays a crucial role in maintaining viral latency."
  }
]